TOP TEN perturbations for 40093_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40093_at
Selected probe(set): 40093_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40093_at (40093_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic)
Relative Expression (log2-ratio):4.180168Number of Samples:2 / 5
| Experimental | expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium. | |
| Control | expO endometrial cancer study 1 (malignant mixed Mullerian tumor; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary malignant mixed Mullerian tumor of the endometrium. |
expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO endometrial cancer study 1 (endometrioid carcinoma; metastatic)
Relative Expression (log2-ratio):3.6395397Number of Samples:2 / 20
| Experimental | expO endometrial cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the endometrium. | |
| Control | expO endometrial cancer study 1 (endometrioid carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the endometrium. |
expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Relative Expression (log2-ratio):-3.3489895Number of Samples:2 / 5
| Experimental | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary. |
expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):2.8321056Number of Samples:51 / 2
| Experimental | expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):2.7713718Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
expO ovary cancer study 1 (carcinoma, NOS; primary) / expO ovary cancer study 1 (adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.744485Number of Samples:2 / 4
| Experimental | expO ovary cancer study 1 (carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS). | |
| Control | expO ovary cancer study 1 (adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with adenocarcinoma (NOS). |
expO ovary cancer study 1 (mucinous adenocarcinoma; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.741272Number of Samples:6 / 2
| Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS). |
ovarian tumor study 28 (serous cystadenocarcinoma) / ovarian tumor study 28 (carcinosarcoma)
Relative Expression (log2-ratio):2.7260733Number of Samples:71 / 2
| Experimental | ovarian tumor study 28 (serous cystadenocarcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with malignant serous cystadenocarcinoma. | |
| Control | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. |
expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Relative Expression (log2-ratio):-2.6801386Number of Samples:3 / 5
| Experimental | expO ovary cancer study 1 (endometrioid carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary. | |
| Control | expO ovary cancer study 1 (carcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary. |
ovarian tumor study 28 (carcinosarcoma) / ovarian tumor study 28 (clear cell adenocarcinoma)
Relative Expression (log2-ratio):-2.5643053Number of Samples:2 / 6
| Experimental | ovarian tumor study 28 (carcinosarcoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with carcinosarcoma. | |
| Control | ovarian tumor study 28 (clear cell adenocarcinoma) |
| Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma. |